Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Guangzhou City, China Clinical Trials

A listing of Guangzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer

Dosimetric verification was performed after implantation. Pre- and postoperative D90, V100, and V150 were calculated. The success rate of iodine-125 seed implantation, dosimetric parameters, objective response rate (ORR)overall survival (OS)toxicities and quality of life of two treatment regimens and complications were analyzed and compared between the two groups.

Phase N/A

0.0 miles

Learn More »

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

This SAST trial is a prospective, multicenter, randomized, double-blind trial.440 acute ischemic stroke (AIS) patients with G6PD deficiency will be randomized to receive a 3-month regimen of aspirin 100mg/d or clopidogrel 75mg/d. The primary end point is the proportion of protocol-defined hemolysis at 90 days. Protocol-defined hemolysis is defined as ...

Phase

0.0 miles

Learn More »

The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment

The chronic obstructive pulmonary disease (COPD) patients with type II respiratory failure always needs PaCO2 test to monitor the changes of disease. Method used mostly nowadays to detect PaCO2 is arterial puncture which is accurate but is invasive, painful and non-dynamic. Noninvasive measurement methods includes end-tidal CO2 (PetCO2), transcutaneous CO2 ...

Phase N/A

0.0 miles

Learn More »

ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis

This is a randomized, cross-over, single-blind trial. After verification of the entry criteria, eligible patients will be, based on the randomization codes, randomly assigned to undergo either capsaicin or ATP cough provocation test (the participants will inhale capasaicin or ATP incremental concentration to induce cough, meanwhile the number of coughs ...

Phase N/A

0.0 miles

Learn More »

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IMP4297 Following First-Line Platinum-based Chemotherapy in the Monotherapy Maintenance Treatment of Subjects with International Federation of Gynecology and Obstetrics (FIGO) Stage III-IV Ovarian Cancer. Subjects with newly diagnosed III/IV high-grade serous ovarian carcinoma (HGSOC) or ...

Phase

0.0 miles

Learn More »

Cancer Genome Atlas of China:Lung Cancer

This project will establish a standardized procedure of lung cancer sample collection, transportation, storage, detection, bioinformatics analysis and result judgment, so as to draw up the gene map of advanced lung cancer in China, and provide an important basis for the research and development of new drugs and the guidance ...

Phase N/A

1.09 miles

Learn More »

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

This is a phase IV, open-labelled, randomized controlled clinical trial. A total of 125 cases who are novel coronavirus positive are planned to be recruited. These cases are randomized into 3 groups: in group AStandard treatment+lopinavir/ritonavir, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir ...

Phase

1.58 miles

Learn More »

TAI Combined With PD-1 Inhibitor in Locally Advanced Potentially Resectable HCC

Sintilimab monoclonal antibody (IBI308) is a recombinant human IgG4 PD-1 monoclonal antibody. It has been proved in many preclinical and in vitro trials that the effect of blocking PD-1 pathway with Sintilimab monoclonal antibody on. The results of preclinical pharmacodynamics, animal pharmacokinetics and toxicology all indicated that Sintilimab monoclonal antibody ...

Phase

1.58 miles

Learn More »

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory ...

Phase

1.8 miles

Learn More »

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the patients who experience disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28 days of continuous dosing. The study includes 4 cohorts.

Phase

2.0 miles

Learn More »